Stockscreener 앱 받기
10.28
2.37%
-0.25
시간 외 거래:
10.27
-0.010
-0.10%
Oric Pharmaceuticals Inc 주식(ORIC)의 최신 뉴스
ORIC Investors Have Opportunity to Join ORIC Pharmaceuticals, Inc. Fraud Investigation with the Schall Law Firm - Business Wire
INVESTOR ALERT: Pomerantz Law Firm Investigates Claims On Behalf of Investors of ORIC Pharmaceuticals, Inc.- ORIC - ChartMill
A Look At ORIC Pharmaceuticals (ORIC) Valuation After Positive Phase 1b Rinzimetostat Trial Update - Sahm
ORIC Pharma drops after early-stage trial data for prostate cancer therapy - MSN
Why ORIC Pharmaceuticals (ORIC) Is Up 14.2% After Advancing Rinzimetostat Combo Into Phase 3 Trial - Sahm
Understanding the Setup: (ORIC) and Scalable Risk - Stock Traders Daily
ORIC Pharmaceuticals stock nosedives 25% after hours: What is going on? - MSN
Here's Why We're Not Too Worried About ORIC Pharmaceuticals' (NASDAQ:ORIC) Cash Burn Situation - Moomoo
Oric Pharmaceuticals Stock Rises 6.5%, Analysts Maintain Buy Ratings - National Today
Oric Pharmaceuticals (NASDAQ:ORIC) Stock Price Up 6.5%Still a Buy? - MarketBeat
ORIC falls after hours on safety concerns around prostate cancer candidate at higher doses - MSN
Oric Pharmaceuticals, Inc. (NASDAQ:ORIC) Receives Consensus Rating of "Moderate Buy" from Brokerages - MarketBeat
JonesTrading Maintains Oric Pharmaceuticals(ORIC.US) With Buy Rating, Raises Target Price to $25 - Moomoo
A Look At ORIC Pharmaceuticals (ORIC) Valuation After Advancing Rinzimetostat To A Phase 3 Prostate Cancer Trial - Sahm
ORIC Pharmaceuticals, Inc. Shareholders Are Encouraged to - GlobeNewswire
A Look At ORIC Pharmaceuticals (ORIC) Valuation After Promising Rinzimetostat Phase 1b Prostate Cancer Data - Yahoo Finance
ORIC Pharmaceuticals Reports Inducement Grants - National Today
ORIC Pharmaceuticals, Inc. (ORIC) stock price, news, quote and history - Yahoo Finance UK
Beyond Meat posts downbeat Q4 results, joins RH, ORIC Pharmaceuticals and other big stocks moving lower in Wednesday's pre-market session - MSN
ORIC Pharmaceuticals (ORIC) Is Down 28.2% After Selecting 400 mg Rinzimetostat Dose for Phase 3 - Sahm
ORIC Pharmaceuticals Reports Inducement Grants under Nasdaq Listing Rule 5635(c)(4) - Sahm
ORIC Pharmaceuticals Faces Volatile Trading Following Latest Clinical Trial Developments - StocksToTrade
ORIC Pharmaceuticals’ Global Ambitions amid Tumultuous Share Movements - StocksToTrade
Oric Pharmaceuticals (NASDAQ:ORIC) Trading 11.6% HigherTime to Buy? - MarketBeat
ORIC Pharmaceuticals Faces Turbulence Amid Prostate Cancer Drug Advancements - timothysykes.com
Investors Purchase Large Volume of Oric Pharmaceuticals Call Options (NASDAQ:ORIC) - MarketBeat
Analysts’ Opinions Are Mixed on These Healthcare Stocks: Diamedica Therapeutics (DMAC), Elevance Health (ELV) and Oric Pharmaceuticals (ORIC) - The Globe and Mail
Oric Pharmaceuticals (ORIC) Receives a Buy from Evercore ISI - The Globe and Mail
HC Wainwright Reiterates Buy Rating for ORIC, Maintains Price Ta - GuruFocus
HC Wainwright Reaffirms Buy Rating for Oric Pharmaceuticals (NASDAQ:ORIC) - marketbeat.com
Oric Pharmaceuticals stock falls on prostate cancer trial data, Sellside Comments - Investing.com Canada
H.C. Wainwright reiterates Buy on ORIC Pharmaceuticals stock By Investing.com - Investing.com Canada
H.C. Wainwright reiterates Buy on ORIC Pharmaceuticals stock - Investing.com
Guggenheim Keeps Their Buy Rating on Oric Pharmaceuticals (ORIC) - The Globe and Mail
HC Wainwright Reiterates Buy Rating for ORIC, Maintains Price Target | ORIC Stock News - GuruFocus
ORIC Stock Pullback Seen as Buying Opportunity - GuruFocus
ORIC Pharmaceuticals (ORIC) Is Down 36.1% After Advancing Lower-Toxicity Prostate Cancer Drug to Phase 3 - Yahoo Finance
ORIC Pharmaceuticals Inc. R (4TZ.HM) Analyst insights, Price targets and Recommendations - Yahoo Finance UK
What's Behind The Drop In Oric Pharmaceuticals Stock Today? - Sahm
What's behind the drop in Oric Pharmaceuticals stock today? - MSN
ORIC: Opportunity Arises in Oric Pharmaceuticals Amid Price Drop - GuruFocus
2.69%
0.25%
자본화:
|
볼륨(24시간):